Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for adults with anaplastic astrocytomas that have not responded
to standard therapy provide very limited benefit to the patient. The anti-cancer properties
of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults
with anaplastic astrocytomas that have not responded to standard therapy.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on adults with anaplastic astrocytomas that have not responded to
standard therapy.